Relationship between ADIPOQ polymorphisms and polycystic ovary syndrome: a meta-analysis involving 6,735 subjects

To address the relationship of ADIPOQ T45G and G276T polymorphisms with polycystic ovary syndrome (PCOS), a meta-analysis was performed in this report. An extensive literature search, selection of eligible publications and extract relevant data were carried out. Sixteen eligible papers with a total number of 2,456 PCOS patients and 4,279 controls met the major including criteria in the pooled analysis on the correlation between ADIPOQ polymorphisms and PCOS. We used crude odds ratios (ORs) with 95% confidence intervals (CIs) to evaluate the strength of relationship. The results demonstrated that there was no evidence for the correlation between ADIPOQ T45G and PCOS even in the subgroup analyses. However, ADIPOQ G276T polymorphism conferred the decreased risk to PCOS in two genetic models: T vs. G (OR, 0.88; 95% CI, 0.78-1.00; P=0.047) and TT+GT vs. GG (OR, 0.80; 95% CI, 0.70-0.93; P=0.003). In a subgroup analysis by ethnicity, the similar findings were also found among Asians in two genetic models: TT vs. GG (OR, 0.55; 95% CI, 0.39-0.78; P=0.001) and TT+GT vs. GG (OR, 0.71; 95% CI, 0.56-0.89; P=0.003). In a subgroup analysis by diagnosis criteria of PCOS, we found that ADIPOQ G276T polymorphism was associated with the decreased risk of PCOS among European Society for Human Reproduction and Embryology/ American Society for Reproductive Medicine criteria (ESHRE/ASRM) in three genetic models: T vs. G (OR, 0.80; 95% CI, 0.66-0.99; P=0.036), TT vs. GG (OR, 0.60; 95% CI, 0.40-0.91; P=0.015) and TT+GT vs. GG (OR, 0.71; 95% CI, 0.59-0.85; P<0.001). In summary, our results suggest that ADIPOQ G276T polymorphism was associated with the decreased risk of PCOS, especially in Asians and ESHRE/ASRM of PCOS subgroups.